Table 2.
Clinicopathological characteristics
| PCNSL (n = 22) | Secondary-CNSL (n = 7) | Other CNSL (n = 7) | p value PCNSL versus SCNSL | p value PCNSL versus Other | |
|---|---|---|---|---|---|
| Age (years) | |||||
| Mean [min–max] | 68 [39–84] | 49 [12–81] | 66 [30–79] | 0.013 | 0.98 |
| Sex | |||||
| Male/female | 15/7 | 3/4 | 2/5 | 0.45 | 0.158 |
| Necrosis | |||||
| % (#) | 23% (5/22) | 0% (0/7) | 57% (4/7) | 0.417 | 0.213 |
| EBV (EBER ISH) | |||||
| 0 | 0 | 5+ | / | / | |
| Immunosuppressive/immunomodulatory therapy | |||||
| 0 | 0 | 4++ | / | / | |
| Prognostic score (IELSG + IPI) | IELSG | IPI | IELSG (n = 4) + IPI (n = 3) | ||
| Low risk (0–1) | 4 | 1 | 1 + 0 | NR | NR |
| Intermediate risk (2, 3) | 11 | 6 | 2 + 1 | ||
| High risk (4) | 1 | 0 | 1 + 2 | ||
| NA (incomplete data) | 6 | 0 | 0 + 0 | ||
| 3 year Overall Survival | |||||
| % (#) | 9% (2/22) | 29% (2/7) | 20% (1/5a) | 0.501 | 1 |
| High-dose MTX in first line | |||||
| Yes/no | 17/5 | 5/2 | 2/5 | 1 | 0.057 |
| Pre-biopsy corticosteroids | |||||
| Yes/no (NA) | 7/13 (2) | 1/6 | 4/3 | 0.581 | 0.562 |
| Hans algorithm IHC | |||||
| GC/non-GC (NA) | 0/19 (3) | 2/4 (1) | 1/4 (2) | 0.078 | 0.463 |
| c-myc IHC positive (> 40%b) | |||||
| % (#) | 36% (8/22) | 29% (2/7) | 14% (1/7) | 1 | 0.53 |
| Bcl2 IHC positive (> 50%b) | |||||
| % (#) | 82% (18/22) | 57% (4/7) | 86% (6/7) | 0.411 | 1 |
| PD-L1 IHC positive | |||||
| % (#) | 23% (5/22) | 29% (2/7) | 43% (3/7) | 1 | 0.581 |
PCNSL primary central nervous system lymphoma (CNSL), EBV Epstein–Barr virus, EBER ISH EBV-encoded RNA in situ hybridization, IELSG International Extranodal Lymphoma Study Group, IPI International Prognostic Index, NR not relevant, MTX methotrexate, IHC immunohistochemistry, GC germinal center
aTwo patients were excluded because diagnosis was only confirmed at the time of autopsy
bPercentage of malignant cells used as threshold for positivity